Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labat AfricaJSE:LAB Days Sales Outstanding is 297.67 as of Nov. 2025, which is 424% above its 10-year median of 56.78. The stock has 5 warning signs investors should review. Among 949 Drug Manufacturers companies, Labat Africa ranks worse than 92.94% on this metric.
Labat Africa's average Accounts Receivable for the
six
months ended in Nov. 2025 was R246.1 Mil. Labat Africa's Revenue for the
six
months ended in Nov. 2025 was R150.9 Mil.
Hence, Labat Africa's Days Sales Outstanding for the
six
months ended in Nov. 2025 was 297.67.
The historical rank and industry rank for Labat Africa's Days Sales Outstanding or its related term are showing as below:
JSE:LAB'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.34 Med: 56.78 Max: 239.69
Current: 196.35
During the past 13 years, Labat Africa's highest Days Sales Outstanding was 239.69. The lowest was 17.34. And the median was 56.78.
JSE:LAB's Days Sales Outstanding is ranked worse than 92.94% of 949
companies
in the Drug Manufacturers industry
Industry Median: 72
vs JSE:LAB: 196.35
Labat Africa's Days Sales Outstanding
increased
from Nov. 2024 (64.68) to Nov. 2025 (297.67).
Labat Africa (JSE:LAB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Labat Africa Days Sales Outstanding Related Terms
Labat Africa Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Labat Africa's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:LAB vs ZTS, UTHR, VTRS: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Labat Africa's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 297.67 mean?
Labat Africa (JSE:LAB) has a Days Sales Outstanding of 297.67 as of Nov. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labat Africa and its competitors. This is 424% above median its historical median of 56.78. Over the past decade, Labat Africa's Days Sales Outstanding has ranged from 17.34 to 239.69. According to the industry distribution chart, Labat Africa ranks #882 out of 949 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Labat Africa's Days Sales Outstanding too high?
Labat Africa's current Days Sales Outstanding of 297.67 is 424% above median its 10-year median of 56.78. Over the past 10 years, this metric has ranged from a low of 17.34 to a high of 239.69. The Drug Manufacturers industry median Days Sales Outstanding is 72.00. Labat Africa's value of 297.67 is 313.4% above this industry median. Based on the distribution chart, Labat Africa ranks #882 out of 949 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Labat Africa's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #882 out of 949 companies for Days Sales Outstanding. This places Labat Africa in the lower half of its industry. The industry median Days Sales Outstanding is 72.00. Labat Africa's value of 297.67 is 313.4% above this benchmark. Historically, Labat Africa's own Days Sales Outstanding has ranged from 17.34 to 239.69 over the past decade. While the company's 10-year median is 56.78 vs. the industry median of 72.00, Labat Africa has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.00, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current Days Sales Outstanding of 297.67 is 313.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current Days Sales Outstanding is 297.67, which is 424% above median its own 10-year median of 56.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current Days Sales Outstanding is 297.67, which is 424% above median its 10-year median of 56.78 and 313.4% above the Drug Manufacturers industry median of 72.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Days Sales Outstanding is 297.67 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 
